Oral Evidence May. 13 2024
Inquiry: Preterm BirthFound: networks and our maternity medicine networks in the way we fund the neonatal networks.
Oral Evidence May. 09 2024
Inquiry: Food, Diet and ObesityFound: If you do not do the early years preventive work, once children get to primary school level, some of
Mentions:
1: Rachael Maskell (LAB - York Central) I worked in respiratory medicine for 20 years, and I saw the devastating impact of smoking on so many - Speech Link
2: Caroline Johnson (Con - Sleaford and North Hykeham) Having worked in respiratory medicine in my very first job as a doctor, I saw far too many people suffering - Speech Link
3: Preet Kaur Gill (LAB - Birmingham, Edgbaston) Durham:“There was no evidence of a serious problem, but the Minister sympathised with the argument for preventive - Speech Link
May. 07 2024
Source Page: Communal accommodation settings: infectious disease transmissionFound: Journal of Travel Medicine 2014: volume 21, issue 5, pages 298 -303 35.
Apr. 30 2024
Source Page: MHRA’s AI regulatory strategy ensures patient safety and industry innovation into 2030Found: about benefitting the UK health technology sector (including 3 Topol, E.J (2019) ‘High -performance medicine
Mentions:
1: Margaret Greenwood (Lab - Wirral West) 600,000 patients are currently on NHS waiting lists to begin treatment for ophthalmology—the branch of medicine - Speech Link
2: Andrew Stephenson (Con - Pendle) We are doing a huge amount to reduce the number, through preventive measures and early detection. - Speech Link
Found: In September 2020, a study of 4 ,000 UK respondents by the London School of Hygiene and Tropical Medicine
Written Evidence Apr. 24 2024
Inquiry: Preterm BirthFound: (Developmental Medicine & Child Neurology 2008, 50: 334– 340.)
Mentions:
1: Mark Spencer (Con - Sherwood) case that a safety concern arises about a product or an active substance—the ingredient that gives a medicine - Speech Link
2: Mark Spencer (Con - Sherwood) something that we are very much looking to do.The shadow Minister asked why we do not fully ban the preventive - Speech Link
Asked by: Henry Smith (Conservative - Crawley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help improve genomics testing for bowel cancer patients.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
A National Health Service testing programme is helping to diagnose thousands of people with a genetic condition, Lynch Syndrome, that increases the chance of developing certain cancers including bowel cancer. The national programme ensures all people diagnosed with bowel cancer are offered genomic testing, with a diagnosis for Lynch Syndrome not only helping to guide more personalised cancer treatment but enabling their families and relatives to be offered testing too. Relatives who receive a diagnosis of Lynch Syndrome can be referred to genetic services to discuss regular testing options to help catch any cancers as early as possible, as well as to consider preventive options such as taking aspirin or undergoing risk-reducing surgery.
Genomic testing in the NHS in England is provided through the NHS Genomic Medicine Service (GMS) and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory (NGTD) which outlines the full range of genomic testing offered by the NHS in England including tests for 3,200 rare diseases and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing. The NGTD sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used, including testing for bowel cancer patients.
The NHS GMS cancer genomic testing strategy has facilitated a move to a consolidated laboratory network through the seven NHS GLHs delivering more extensive panel testing using cutting edge high throughput Next Generation Sequencing (NGS) technology. For patients, including those with bowel cancer, this technology enables testing for a larger number of genetic variations to give a more precise diagnosis, identify biomarkers to target treatment and opportunities to access innovative medicines, and can support enrolment into molecularly stratified clinical trials.
Testing is available for all eligible patients across the whole of England. Individuals should discuss with their healthcare professional (for example, their general practitioner or other healthcare professional if they are already being seen in a relevant service) whether genomic testing is appropriate for them. Their healthcare professional will then make a decision whether to refer the individual either directly or via an NHS clinical genomics service or other relevant clinical speciality for genomic testing following clinical review of their and their family’s medical history if known, and the relevant genomic testing eligibility criteria.
The 17 NHS Clinical Genomic Services (NHS CGSs), commissioned by NHS England, deliver a comprehensive clinical genomic and counselling service that directs the diagnosis, risk assessment and lifelong clinical management of patients of all ages and their families who have, or are at risk of having, a rare genetic or genomic condition. As part of the NHS CGS, the patient and their family will access diagnosis, and management relevant to their particular condition, but also receive support and guidance so that they are able to understand their condition, its implications, and their options in relation to reproduction, screening, prevention and clinical management.